Discovery of unique brain tumor subtypes offers hope for targeted glioma therapies

Researchers have uncovered the mechanisms behind three unique subtypes of mismatch repair deficient high-grade gliomas. The ...
ascopubs.org

Frequency and Impact of Constitutional Mismatch Repair Deficiency in Patients With High-Grade Glioma, a Retrospective Analysis of 7 Years in Pakistan: an IRRDC Study

Targeted Next-Generation Sequencing of Cell-Free DNA to Detect MYC-Immunoglobulin Translocation and Epstein-Barr Virus DNA in Plasma of Burkitt Lymphoma Patients in East Africa The following ...
ascopubs.org

Somatic mismatch repair deficiency in pancreas cancer (PC): Immune checkpoint blockade (ICB) outcomes and exploratory genomic analyses.

FG-M108 plus nab-paclitaxel and gemcitabine (AG) as first-line (1L) treatment for patients with Claudin-18.2 (CLDN18.2) positive locally advanced unresectable or metastatic pancreatic cancer (PC): ...
EurekAlert!

Neoadjuvant PD-1 blockade in early-stage mismatch repair-deficient cancers can eliminate the need for surgery regardless of tumor type

CHICAGO – PD-1 blockade with dostarlimab (Jemperli) induced complete tumor clearance and resolved the need for surgery in patients with locally advanced, mismatch repair-deficient (dMMR) cancers, ...
Cure Today

FDA Approves Dako Omnis Test to Guide Colorectal Cancer Treatment

The FDA approved the Dako Omnis panel to identify patients with colorectal cancer with mismatch repair deficiency. The mismatch repair immunohistochemical panel pharmDx (Dako Omnis) has received U.S.